Sarasate M., González N., Córdoba-Izquierdo A., Prats E., Gonzalez-Moro, JMR, Martí S., Lujan M., Calle M., Antón A., Povedano M., Farrero E.. Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial. Journal Of Neuromuscular Diseases. 2023; 10(4)DOI:10.3233/JND-221658. PMID:37212068. IF:3.200(Q2/3D).

Provencio M., Ortega A.L., Coves-Sarto J., Calvo V., Marsé-Fabregat R., Dómine M., Guirado M., Carcereny E., Fernández N., Álvarez R., Blanco R., León-Mateos L., Sánchez-Torres J.M., Sullivan I.G., Cobo M., Sánchez-Hernández A., Massuti B., Sierra-Rodero B., Mártinez-Toledo C., Serna-Blasco R., Romero A., Cruz-Bermúdez A.. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer with High Tumor Mutation Burden: A Nonrandomized Controlled Trial. JAMA Oncology. 2023; 9(3)DOI:10.1001/jamaoncol.2022.5959. PMID:36520426. IF:22.300(Q1/1D).

Bertran-Alamillo J., Giménez-Capitán A., Román R., Talbot S., Whiteley R., Floc’h N., Martínez-Pérez E., Martin M.J., Smith P.D., Sullivan I., Terp M.G., Saeh J., Marino-Buslje C., Fabbri G., Guo G., Xu M., Tornador C., Aguilar-Hernández A., Reguart N., Ditzel H.J., Martínez-Bueno A., Nabau-Moretó N., Gascó A., Rosell R., Pease J.E., Polanska U.M., Travers J., Urosevic J., Molina-Vila M.A.. BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors. Molecular Cancer. 2023; 22(1)DOI:10.1186/s12943-023-01815-w. PMID:37443114. IF:27.700(Q1/1D).

Blanco R., Dómine M., González J.L., Loutfi S., Alfaro J., Saldaña J., Rubio J., Campos B., Hidalgo J., Barba A., Márquez D., Martin M., Olaverri A., Nadal E.. Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes. LUNG CANCER. 2023; 183DOI:10.1016/j.lungcan.2023.107318. PMID:37557022. IF:4.500(Q1/2D).